Loading...

ENTX ENTERA BIO LTD Expansion Plans 8-K Filing

NTR

NTX

ENTERA BIO LTD

(ENTX)

2026 8-K

Financial Results Update

Funding Agreement Signed

Financial Results Update

FDA Submission Update

Management Changes

Leadership Change

Financial Results Announced

New Drug Application Agreement

Financial Statements

Financial Results

Collaboration Agreement

Advisory Vote Update

Financial Results

Financial Results Announcement

Annual Meeting Voting Results

Financial Results Announcement

Financial Results Announcement

Compliance Regained

Registration Statement Filed

Extension for Compliance wi...

Private Placement

Earnings Report

Annual Meeting Voting Results

Financial Results Announcement

Appointment of Director

Earnings Report

Earnings Report

External Links:

On March 4, 2026, Entera Bio Ltd. submitted a Phase 3 protocol to the FDA for EB613, aimed at treating postmenopausal women with osteoporosis. This significant filing reflects the company's advancement in its product development pipeline.

AI Assistant

ENTERA BIO LTD

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.